IL-2Rα-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction

Cancer Research

Volumn 60, Issue 24, 2000, Pages 6977-6984

  Phillips, Kathleen E ^a   Herring, Bert ^a   Wilson, Latresia A ^a   Rickford, Marc S ^a   Zhang, Meili ^a   Goldman, Carolyn K ^a   Yun Tso, J ^b   Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE; EPITOPE; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; COMPLEMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; ANIMAL; B LYMPHOCYTE; BLOOD; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; LEUKEMIA; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; T LYMPHOCYTE; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BETA 2-MICROGLOBULIN; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LEUKEMIA, T-CELL; MICE; MICE, INBRED NOD; MICE, SCID; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TIME FACTORS;

EID: 0034670370     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Adult T-cell leukemia: Clinical and hematologic features of 16 cases
2. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)
3. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma
4. A hypothesis on the etiology of adult T-cell leukemia/lymphoma
5. Adult T-cell lymphoma-leukaemia in Blacks from the West Indies
6. The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma
7. Human adult T-cell leukemia virus: Molecular cloning of the provirus DNA and the unique terminal structure
8. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
9. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor
10. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells
11. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia
12. Autocrine growth of interleukin 2-producing leukemic cells in a patient with adult T cell leukemia
13. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy
14. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine
15. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2
16. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice
17. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
18. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac
19. Preparation of a bispecific F(ab′)2 targeted to the human IL-2 receptor
20. A model of in vivo cell proliferation of adult T-cell leukemia
21. Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice
22. The use of antibodies against the IL-2 receptor in transplantation
23. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
24. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac
25. Immune receptors: Targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection
26. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
27. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac
28. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A Phase I/II clinical trial
29. Cytokine: Induction in HTLV-I associated myelopathy and adult T-cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis
30. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
31. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells
32. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-κB site
33. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells
34. Fc receptors are required in passive and active immunity to melanoma
35. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
36. Fas and the art of lymphocyte maintenance
37. Differential activation of antigen-stimulated suicide and cytokine production pathways in CD4 + T cells is regulated by the antigen-presenting cell
38. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis